Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations

Detalhes bibliográficos
Autor(a) principal: Santos, K.F.R.
Data de Publicação: 1999
Outros Autores: Oliveira, T.T., Nagem, T.J., Pinto, A.S., Oliveira, M.G.A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: LOCUS Repositório Institucional da UFV
Texto Completo: https://doi.org/10.1006/phrs.1999.0556
http://www.locus.ufv.br/handle/123456789/19658
Resumo: Atherosclerosis can be defined as being a disease of coronary circulation. The present work evaluates the action of the naringenin, rutin, nicotinic acid, isolated and in association, on the metabolism of lipids. Cholesterol, cholesterol HDL, and triacylglycerols have been dosed after retreat of blood, following the administration of the compounds dissolved in propylene glycol by intraperitoneal route in doses of 5 mg kg^−1body wt. Results evidence that naringenin and nicotinic acid, isolated as well as their association with naringenin and nicotinic acid–rutin, present the largest percentual reduction of cholesterol. On the other hand, the best results for cholesterol-HDL have been obtained with naringenin, while rutin has shown the best triacylglycerols levels.
id UFV_6a6913e5746be7b7f9180f091b403741
oai_identifier_str oai:locus.ufv.br:123456789/19658
network_acronym_str UFV
network_name_str LOCUS Repositório Institucional da UFV
repository_id_str 2145
spelling Santos, K.F.R.Oliveira, T.T.Nagem, T.J.Pinto, A.S.Oliveira, M.G.A.2018-05-17T17:31:56Z2018-05-17T17:31:56Z1999-05-2610436618https://doi.org/10.1006/phrs.1999.0556http://www.locus.ufv.br/handle/123456789/19658Atherosclerosis can be defined as being a disease of coronary circulation. The present work evaluates the action of the naringenin, rutin, nicotinic acid, isolated and in association, on the metabolism of lipids. Cholesterol, cholesterol HDL, and triacylglycerols have been dosed after retreat of blood, following the administration of the compounds dissolved in propylene glycol by intraperitoneal route in doses of 5 mg kg^−1body wt. Results evidence that naringenin and nicotinic acid, isolated as well as their association with naringenin and nicotinic acid–rutin, present the largest percentual reduction of cholesterol. On the other hand, the best results for cholesterol-HDL have been obtained with naringenin, while rutin has shown the best triacylglycerols levels.engPharmacological Researchv. 40, n. 6, p. 493-496, Dezembro 1999Academic Pressinfo:eu-repo/semantics/openAccessNaringeninRutinNicotinic acidHypolipidemic actionRatsHypolipidaemic effects of naringenin, rutin, nicotinic acid and their associationsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfreponame:LOCUS Repositório Institucional da UFVinstname:Universidade Federal de Viçosa (UFV)instacron:UFVORIGINALartigo.pdfartigo.pdftexto completoapplication/pdf75127https://locus.ufv.br//bitstream/123456789/19658/1/artigo.pdf7205d20be360ee6443949314a79a4b72MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://locus.ufv.br//bitstream/123456789/19658/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILartigo.pdf.jpgartigo.pdf.jpgIM Thumbnailimage/jpeg4819https://locus.ufv.br//bitstream/123456789/19658/3/artigo.pdf.jpg86f24e6f1c822575008e546aff422a6eMD53123456789/196582018-05-17 23:00:35.856oai:locus.ufv.br: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Repositório InstitucionalPUBhttps://www.locus.ufv.br/oai/requestfabiojreis@ufv.bropendoar:21452018-05-18T02:00:35LOCUS Repositório Institucional da UFV - Universidade Federal de Viçosa (UFV)false
dc.title.en.fl_str_mv Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
title Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
spellingShingle Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
Santos, K.F.R.
Naringenin
Rutin
Nicotinic acid
Hypolipidemic action
Rats
title_short Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
title_full Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
title_fullStr Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
title_full_unstemmed Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
title_sort Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations
author Santos, K.F.R.
author_facet Santos, K.F.R.
Oliveira, T.T.
Nagem, T.J.
Pinto, A.S.
Oliveira, M.G.A.
author_role author
author2 Oliveira, T.T.
Nagem, T.J.
Pinto, A.S.
Oliveira, M.G.A.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Santos, K.F.R.
Oliveira, T.T.
Nagem, T.J.
Pinto, A.S.
Oliveira, M.G.A.
dc.subject.pt-BR.fl_str_mv Naringenin
Rutin
Nicotinic acid
Hypolipidemic action
Rats
topic Naringenin
Rutin
Nicotinic acid
Hypolipidemic action
Rats
description Atherosclerosis can be defined as being a disease of coronary circulation. The present work evaluates the action of the naringenin, rutin, nicotinic acid, isolated and in association, on the metabolism of lipids. Cholesterol, cholesterol HDL, and triacylglycerols have been dosed after retreat of blood, following the administration of the compounds dissolved in propylene glycol by intraperitoneal route in doses of 5 mg kg^−1body wt. Results evidence that naringenin and nicotinic acid, isolated as well as their association with naringenin and nicotinic acid–rutin, present the largest percentual reduction of cholesterol. On the other hand, the best results for cholesterol-HDL have been obtained with naringenin, while rutin has shown the best triacylglycerols levels.
publishDate 1999
dc.date.issued.fl_str_mv 1999-05-26
dc.date.accessioned.fl_str_mv 2018-05-17T17:31:56Z
dc.date.available.fl_str_mv 2018-05-17T17:31:56Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.1006/phrs.1999.0556
http://www.locus.ufv.br/handle/123456789/19658
dc.identifier.issn.none.fl_str_mv 10436618
identifier_str_mv 10436618
url https://doi.org/10.1006/phrs.1999.0556
http://www.locus.ufv.br/handle/123456789/19658
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartofseries.pt-BR.fl_str_mv v. 40, n. 6, p. 493-496, Dezembro 1999
dc.rights.driver.fl_str_mv Academic Press
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Academic Press
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Pharmacological Research
publisher.none.fl_str_mv Pharmacological Research
dc.source.none.fl_str_mv reponame:LOCUS Repositório Institucional da UFV
instname:Universidade Federal de Viçosa (UFV)
instacron:UFV
instname_str Universidade Federal de Viçosa (UFV)
instacron_str UFV
institution UFV
reponame_str LOCUS Repositório Institucional da UFV
collection LOCUS Repositório Institucional da UFV
bitstream.url.fl_str_mv https://locus.ufv.br//bitstream/123456789/19658/1/artigo.pdf
https://locus.ufv.br//bitstream/123456789/19658/2/license.txt
https://locus.ufv.br//bitstream/123456789/19658/3/artigo.pdf.jpg
bitstream.checksum.fl_str_mv 7205d20be360ee6443949314a79a4b72
8a4605be74aa9ea9d79846c1fba20a33
86f24e6f1c822575008e546aff422a6e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv LOCUS Repositório Institucional da UFV - Universidade Federal de Viçosa (UFV)
repository.mail.fl_str_mv fabiojreis@ufv.br
_version_ 1798053223907459072